Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 4/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593646 | 1.00 | MAPK13 (0.61) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL29593811 | 0.91 | MAPK13 (0.64) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4239778 | 0.91 | MAPK13 (0.64) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL29593689 | 0.88 | MAPK13 (0.78) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4238182 | 0.88 | MAPK13 (0.78) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4237534 | 0.88 | MAPK13 (0.78) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL29593359 | 0.88 | MAPK13 (0.78) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4236691 | 0.87 | MAPK13 (0.64) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL29593309 | 0.87 | MAPK13 (0.64) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4711410 | 0.87 | MAPK13 (0.60) | MAPK13MAPK11CYP2C9FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1919919-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026950-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK13 303/4885MAPK11 857/4885CYP2C9 4736/4885 |
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | HRH2, OPRD1, HRH4 | MAPK13 1439/4885MAPK11 1195/4885CYP2C9 359/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK13 303/4885MAPK11 857/4885CYP2C9 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.